Global AI Lung Screening System Supply, Demand and Key Producers, 2026-2032
Description
The global AI Lung Screening System market size is expected to reach $ 763 million by 2032, rising at a market growth of 11.9% CAGR during the forecast period (2026-2032).
AI Lung Screening System is an integrated software-driven solution that supports early detection and risk stratification of lung cancer—primarily by analyzing low-dose CT (LDCT) scans in screening or incidental nodule workflows. The system typically performs automated lung nodule detection, segmentation, volumetry, growth tracking, malignancy risk scoring, and structured reporting, aiming to reduce radiologist workload, improve consistency, and standardize follow-up recommendations. In practice, it functions as a clinical decision support layer within radiology operations: it flags suspicious findings, prioritizes worklists, and helps quantify change over time. Commercially, “system” usually refers to a deployable product package (software + workflow integration + validation/regulatory package), rather than an algorithm alone, and is increasingly delivered as a platform with continuous model updates, audit trails, and performance monitoring.
From a multi-angle segmentation standpoint, the market can be parameterized by: (1) Clinical scenario: population LDCT screening vs incidental pulmonary nodules; (2) Algorithmic functions: detection-only, detection+volumetry, full risk scoring (e.g., malignancy probability), and longitudinal tracking; (3) Deployment: on-premise server, private cloud, public cloud/SaaS, or hybrid; (4) Integration depth: standalone viewer vs PACS/RIS embedded workflow with structured reporting; (5) Regulatory class & claims: CAD support vs triage vs quantified decision support. Additional quantitative “type” parameters include supported CT slice thickness, acceptable dose range, nodule size range (e.g., ≥3 mm), sensitivity at fixed false-positive rates, throughput (studies/hour), and interoperability standards (DICOM, HL7/FHIR).
In transaction terms, pricing commonly follows (a) annual subscription per site, (b) per-scan fee, or (c) enterprise license tied to volume tiers, with separate charges for integration, validation support, and service-level agreements. Procurement often runs through hospital IT/security reviews and radiology leadership, with pilots (3–6 months) preceding multi-year contracts. Key trends include tighter workflow embedding (worklist triage + structured reporting), expansion from single-task CAD to end-to-end nodule management, growing emphasis on generalizability and bias control across scanners and populations, and integration of multimodal data (clinical risk factors, prior imaging) to improve risk stratification. As screening volumes rise and radiologist shortages persist, vendors that can prove reduced recall burden, stable false-positive control, and seamless integration are best positioned for durable share gains.
This report studies the global AI Lung Screening System demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for AI Lung Screening System, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of AI Lung Screening System that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global AI Lung Screening System total market, 2021-2032, (USD Million)
Global AI Lung Screening System total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: AI Lung Screening System total market, key domestic companies, and share, (USD Million)
Global AI Lung Screening System revenue by player, revenue and market share 2021-2026, (USD Million)
Global AI Lung Screening System total market by Type, CAGR, 2021-2032, (USD Million)
Global AI Lung Screening System total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global AI Lung Screening System market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lunit, Aidoc, VUNO, Inc., Riverain Technologies, LLC, Viz.ai, RapidAI, Enlitic, ANNALISE-AI PTY LTD, INFERVISION TECHNOLOGY, Lianying Intelligent Medical Technology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world AI Lung Screening System market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global AI Lung Screening System Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global AI Lung Screening System Market, Segmentation by Type:
Lung Cancer Early Screening
Pulmonary Nodule Detection & Tracking
High-Risk Population Screening
Incidental Lung Finding Screening
Others
Global AI Lung Screening System Market, Segmentation by Imaging Modality & Data Source:
LDCT-based Screening System
Standard Chest CT AI System
Others
Global AI Lung Screening System Market, Segmentation by Deployment & Integration Model:
On-premise
Private Cloud (Hospital-owned Cloud)
Public Cloud / SaaS
Others
Global AI Lung Screening System Market, Segmentation by Application:
Medical Institutions
Great Health Scene
Companies Profiled:
Lunit
Aidoc
VUNO, Inc.
Riverain Technologies, LLC
Viz.ai
RapidAI
Enlitic
ANNALISE-AI PTY LTD
INFERVISION TECHNOLOGY
Lianying Intelligent Medical Technology
Key Questions Answered
1. How big is the global AI Lung Screening System market?
2. What is the demand of the global AI Lung Screening System market?
3. What is the year over year growth of the global AI Lung Screening System market?
4. What is the total value of the global AI Lung Screening System market?
5. Who are the Major Players in the global AI Lung Screening System market?
6. What are the growth factors driving the market demand?
AI Lung Screening System is an integrated software-driven solution that supports early detection and risk stratification of lung cancer—primarily by analyzing low-dose CT (LDCT) scans in screening or incidental nodule workflows. The system typically performs automated lung nodule detection, segmentation, volumetry, growth tracking, malignancy risk scoring, and structured reporting, aiming to reduce radiologist workload, improve consistency, and standardize follow-up recommendations. In practice, it functions as a clinical decision support layer within radiology operations: it flags suspicious findings, prioritizes worklists, and helps quantify change over time. Commercially, “system” usually refers to a deployable product package (software + workflow integration + validation/regulatory package), rather than an algorithm alone, and is increasingly delivered as a platform with continuous model updates, audit trails, and performance monitoring.
From a multi-angle segmentation standpoint, the market can be parameterized by: (1) Clinical scenario: population LDCT screening vs incidental pulmonary nodules; (2) Algorithmic functions: detection-only, detection+volumetry, full risk scoring (e.g., malignancy probability), and longitudinal tracking; (3) Deployment: on-premise server, private cloud, public cloud/SaaS, or hybrid; (4) Integration depth: standalone viewer vs PACS/RIS embedded workflow with structured reporting; (5) Regulatory class & claims: CAD support vs triage vs quantified decision support. Additional quantitative “type” parameters include supported CT slice thickness, acceptable dose range, nodule size range (e.g., ≥3 mm), sensitivity at fixed false-positive rates, throughput (studies/hour), and interoperability standards (DICOM, HL7/FHIR).
In transaction terms, pricing commonly follows (a) annual subscription per site, (b) per-scan fee, or (c) enterprise license tied to volume tiers, with separate charges for integration, validation support, and service-level agreements. Procurement often runs through hospital IT/security reviews and radiology leadership, with pilots (3–6 months) preceding multi-year contracts. Key trends include tighter workflow embedding (worklist triage + structured reporting), expansion from single-task CAD to end-to-end nodule management, growing emphasis on generalizability and bias control across scanners and populations, and integration of multimodal data (clinical risk factors, prior imaging) to improve risk stratification. As screening volumes rise and radiologist shortages persist, vendors that can prove reduced recall burden, stable false-positive control, and seamless integration are best positioned for durable share gains.
This report studies the global AI Lung Screening System demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for AI Lung Screening System, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of AI Lung Screening System that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global AI Lung Screening System total market, 2021-2032, (USD Million)
Global AI Lung Screening System total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: AI Lung Screening System total market, key domestic companies, and share, (USD Million)
Global AI Lung Screening System revenue by player, revenue and market share 2021-2026, (USD Million)
Global AI Lung Screening System total market by Type, CAGR, 2021-2032, (USD Million)
Global AI Lung Screening System total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global AI Lung Screening System market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Lunit, Aidoc, VUNO, Inc., Riverain Technologies, LLC, Viz.ai, RapidAI, Enlitic, ANNALISE-AI PTY LTD, INFERVISION TECHNOLOGY, Lianying Intelligent Medical Technology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world AI Lung Screening System market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global AI Lung Screening System Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global AI Lung Screening System Market, Segmentation by Type:
Lung Cancer Early Screening
Pulmonary Nodule Detection & Tracking
High-Risk Population Screening
Incidental Lung Finding Screening
Others
Global AI Lung Screening System Market, Segmentation by Imaging Modality & Data Source:
LDCT-based Screening System
Standard Chest CT AI System
Others
Global AI Lung Screening System Market, Segmentation by Deployment & Integration Model:
On-premise
Private Cloud (Hospital-owned Cloud)
Public Cloud / SaaS
Others
Global AI Lung Screening System Market, Segmentation by Application:
Medical Institutions
Great Health Scene
Companies Profiled:
Lunit
Aidoc
VUNO, Inc.
Riverain Technologies, LLC
Viz.ai
RapidAI
Enlitic
ANNALISE-AI PTY LTD
INFERVISION TECHNOLOGY
Lianying Intelligent Medical Technology
Key Questions Answered
1. How big is the global AI Lung Screening System market?
2. What is the demand of the global AI Lung Screening System market?
3. What is the year over year growth of the global AI Lung Screening System market?
4. What is the total value of the global AI Lung Screening System market?
5. Who are the Major Players in the global AI Lung Screening System market?
6. What are the growth factors driving the market demand?
Table of Contents
96 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World AI Lung Screening System Companies Competitive Analysis
- 4 United States VS China VS Rest of World (by Headquarter Location)
- 5 Market Analysis by Type
- 6 Market Analysis by Imaging Modality & Data Source
- 7 Market Analysis by Deployment & Integration Model
- 8 Market Analysis by Application
- 9 Company Profiles
- 10 Industry Chain Analysis
- 11 Research Findings and Conclusion
- 12 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
